During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

Personalized cancer medicine based on the genetic milieu of individual colorectal tumors
has long been postulated, but until recently this concept was not supported by clinical …

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

Background The epidermal growth factor receptor (EGFR), which participates in signaling
pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer …

The development of noninvasive methods to detect and monitor tumors continues to be a
major challenge in oncology. We used digital polymerase chain reaction–based …

Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor
(EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC) …

Background No treatment options are available for patients with metastatic colorectal cancer
that progresses after all approved standard therapies, but many patients maintain a good …

Background Following the discovery that mutant KRAS is associated with resistance to anti-
epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …

Purpose Panitumumab is a fully human monoclonal antibody directed against the epidermal
growth factor receptor (EGFR). We compared the activity of panitumumab plus best …